Valsts: Amerikas Savienotās Valstis
Valoda: angļu
Klimata pārmaiņas: NLM (National Library of Medicine)
Valproic Acid (UNII: 614OI1Z5WI) (Valproic Acid - UNII:614OI1Z5WI)
Precision Dose Inc.
Valproic Acid
Valproic Acid 500 mg in 10 mL
ORAL
PRESCRIPTION DRUG
Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precaution (5.1) for statement regarding fatal hepatic dysfunction. Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who a
Valproic Acid Oral Solution, USP is available as a clear, cherry-flavored red oral solution containing the equivalent of 250 mg of valproic acid per 5 mL as the sodium salt. NDC 68094-193-61 5 mL per unit dose cup One hundred (100) cups per shipper NDC 68094-193-62 5 mL per unit dose cup Thirty (30) cups per shipper NDC 68094-701-61 10 mL per unit dose cup One hundred (100) cups per shipper NDC 68094-701-62 10 mL per unit dose cup Thirty (30) cups per shipper RECOMMENDED STORAGE Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.
Abbreviated New Drug Application
VALPROIC ACID- VALPROIC ACID SOLUTION Precision Dose Inc. ---------- MEDICATION GUIDE VALPROIC ACID ORAL SOLUTION Read this Medication Guide before you start taking valproic acid oral solution and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about valproic acid oral solution? Do not stop taking valproic acid oral solution without first talking to your healthcare provider. Stopping valproic acid oral solution suddenly can cause serious problems. Valproic acid oral solution can cause serious side effects, including: 1. Serious liver damage that can cause death, especially in children younger than 2 years old. The risk of getting this serious liver damage is more likely to happen within the first 6 months of treatment. Call your healthcare provider right away if you get any of the following symptoms: • nausea or vomiting that does not go away • loss of appetite • pain on the right side of your stomach (abdomen) • dark urine • swelling of your face • yellowing of your skin or the whites of your eyes In some cases, liver damage may continue despite stopping the drug. 2. Valproic acid oral solution may harm your unborn baby. • If you take valproic acid oral solution during pregnancy for any medical condition, your baby is at risk for serious birth defects that affect the brain and spinal cord and are called spina bifida or neural tube defects. These defects occur in 1 to 2 out of every 100 babies born to mothers who use this medicine during pregnancy. These defects can begin in the first month, even before you know you are pregnant. Other birth defects that affect the structures of the heart, head, arms, legs, and the opening where the urine comes out (urethra) on the bottom of the penis can also happen. • Birth defects may occur even in children born to women who are not taking any medicines and do not have other ris Izlasiet visu dokumentu
VALPROIC ACID- VALPROIC ACID SOLUTION PRECISION DOSE INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE VALPROIC ACID ORAL SOLUTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR VALPROIC ACID ORAL SOLUTION. VALPROIC ACID ORAL SOLUTION, USP INITIAL U.S. APPROVAL: 1978 WARNINGS: LIFE THREATENING ADVERSE REACTIONS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ HEPATOTOXICITY, INCLUDING FATALITIES, USUALLY DURING THE FIRST 6 MONTHS OF TREATMENT. CHILDREN UNDER THE AGE OF TWO YEARS AND PATIENTS WITH MITOCHONDRIAL DISORDERS ARE AT HIGHER RISK. MONITOR PATIENTS CLOSELY, AND PERFORM SERUM LIVER TESTING PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER (5.1) FETAL RISK, PARTICULARLY NEURAL TUBE DEFECTS, OTHER MAJOR MALFORMATIONS, AND DECREASED IQ (5.2, 5.3, 5.4) PANCREATITIS, INCLUDING FATAL HEMORRHAGIC CASES (5.5) RECENT MAJOR CHANGES Boxed Warning, Fetal Risk 2/2019 Indications and Usage, Important Limitations (1.2) 2/2019 Contraindications (4) 2/2019 Warnings and Precautions, Use in Women of Childbearing Potential (5.4) 2/2019 INDICATIONS AND USAGE Valproic Acid Oral Solution is indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1) DOSAGE AND ADMINISTRATION Valproic Acid Oral Solution is intended for oral administration. (2.1) Simple and Complex Absence Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/week until seizure control or limiting side effects (2.1) Safety of doses above 60 mg/kg/day is not established (2.1, 2.2) DOSAGE FORMS AND STRENGTHS Oral Solution: Equivalent of 250 mg valproic acid per 5 mL as the sodium salt (3) CONTRAINDICATIONS Hepatic disease or significant hepatic dysfunction (4, 5.1) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( Izlasiet visu dokumentu